These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 920261)

  • 1. The effects of four months' treatment with spironolactone on systemic blood pressure, cardiac output and plasma renin activity in hypertensive patients.
    Bevegård S; Castenfors J; Danielson M
    Acta Med Scand; 1977; 202(5):373-7. PubMed ID: 920261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence of hypertension in primary aldosteronism after discontinuation of spironolactone. Time course of changes in cardiac output and body fluid volumes.
    Wenting GJ; Man in 't Veld AJ; Derkx FH; Schalekamp MA
    Clin Exp Hypertens A; 1982; 4(9-10):1727-48. PubMed ID: 6754151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemodynamic effects of saluretic treatment and beta-receptor blockade in patients with essential hypertension.
    Bevegård S; Castenfors J; Danielson M
    Acta Med Scand; 1977 Jan; 201(1-2):99-104. PubMed ID: 835380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodynamic effects of four months' mefruside therapy in hypertensive patients.
    Bevegård S; Castenfors J; Danielson M
    Acta Med Scand; 1977 Jan; 201(1-2):93-7. PubMed ID: 835379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemodynamic effects of treatment and withdrawal of spironolactone in essential hypertension.
    Falch DK; Johansson R; Odegaard AE; Norman N
    Scand J Clin Lab Invest; 1979 Apr; 39(2):159-65. PubMed ID: 523964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlations between blood pressure, blood volume and plasma renin during therapy with diuretics in essential hypertension. Comparison between the mineralocorticoid antagonist spironolactone and the "loop" diuretic mefruside].
    Beretta-Piccoli C; Weidmann P; de Châtel R; Hirsch D; Reubi FC
    Schweiz Med Wochenschr; 1977 Jan; 107(4):104-15. PubMed ID: 834983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar effects of hydrochlorothiazide and spironolactone on plasma renin activity in essential hypertension.
    Acchiardo S; Dustan HP; Tarazi RC
    Cleve Clin Q; 1972; 39(4):153-62. PubMed ID: 4660197
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation.
    Papadimitriou M; Vyzantiadis A; Milionis A; Memmos D; Metaxas P
    Life Support Syst; 1983; 1(3):197-205. PubMed ID: 6433115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
    Mahmud A; Feely J
    Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic and plasma renin effects of propranolol in essential hypertension.
    Mookherjee S; Eich RH; Obeid AI; Smulyan H
    Arch Intern Med; 1977 Mar; 137(3):290-5. PubMed ID: 843147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.
    Brown JJ; Davies DL; Ferriss JB; Fraser R; Haywood E; Lever AF; Robertson JI
    Br Med J; 1972 Jun; 2(5816):729-34. PubMed ID: 4338668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of aspirin to antagonize the antihypertensive effect of spironolactone in low-renin hypertension.
    Hollifield JW
    South Med J; 1976 Aug; 69(8):1034-6. PubMed ID: 785608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autonomic blockade and the Valsalva maneuver in patients on maintenance hemodialysis: a hemodynamic study.
    McGrath BP; Tiller DJ; Bune A; Chalmers JP; Korner PI; Uther JB
    Kidney Int; 1977 Oct; 12(4):294-302. PubMed ID: 599840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled treatment of primary hypertension with propranolol and spironolactone. A crossover study with special reference to initial plasma renin activity.
    Karlberg BE; Kågedal B; Tegler L; Tolagen K; Bergman B
    Am J Cardiol; 1976 Mar; 37(4):642-9. PubMed ID: 769527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic and endocrine responses to guanfacine in normotensive volunteers and hypertensive patients.
    Rosenthal JH
    Am J Cardiol; 1986 Mar; 57(9):22E-26E. PubMed ID: 3513526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relations between hypotensive effect and modifications of volemia and plasma renin activity in patients with essential hypertension treated using spironolactone].
    Pessina AC; Corgnati A; Palù CD
    Minerva Med; 1977 Feb; 68(8):509-14. PubMed ID: 846681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between the effects of ST 600 and catapres.
    Kho TL; Schalekamp MA; Zaal GA; Wester A; Birkenhäger WH
    Arch Int Pharmacodyn Ther; 1975 Apr; 214(2):347-50. PubMed ID: 1156039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of chlorthalidone and spironolactone in low--renin essential hypertension.
    Kreeft JH; Larochelle P; Ogilvie RI
    Can Med Assoc J; 1983 Jan; 128(1):31-4. PubMed ID: 6336600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic effect of pindolol in essential hypertension with special reference to the resistance and capacitance vessels of the forearm.
    Atterhög JH; Dunér H; Pernow B
    Acta Med Scand; 1976; 199(4):251-5. PubMed ID: 1266662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.